Page last updated: 2024-10-21

4-aminopyridine and Chronic Disease

4-aminopyridine has been researched along with Chronic Disease in 27 studies

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"Systemic administration of pilocarpine to adult rats induces an acute status epilepticus followed by spontaneous recurrent seizures after a 1-2-week silent period."7.69Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures. ( Avoli, M; Gloor, P; Nagao, T, 1994)
" The effects of selective block of I(Kur) by low concentrations of 4-aminopyridine or the biphenyl derivative AVE 0118 were investigated on right atrial action potentials (APs) in trabeculae from patients in sinus rhythm (SR) or chronic atrial fibrillation (AF)."3.72Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. ( Christ, T; Dobrev, D; Hála, O; Heubach, JF; Knaut, M; Ravens, U; Varró, A; Wettwer, E, 2004)
"Systemic administration of pilocarpine to adult rats induces an acute status epilepticus followed by spontaneous recurrent seizures after a 1-2-week silent period."3.69Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures. ( Avoli, M; Gloor, P; Nagao, T, 1994)
" Fourteen (56%) patients had 26 adverse reactions."2.71Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. ( Arenas-Hernández, R; Castañeda-Hernández, G; Grijalva, I; Guízar-Sahagún, G; Ibarra, A; Maldonado-Julián, H; Mino, D; Salgado-Ceballos, H; Serra, O; Vidal-Cantú, G, 2003)
" Safety assessments: physical examinations, vital sign measurements, clinical laboratory tests, electrocardiogram recordings, and adverse events."2.71Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ( Blight, AR; Cohen, R; Hayes, KC; Hsieh, JT; Katz, MA; Potter, PJ, 2004)
" A statistically significant difference in the initial rate and extent of absorption, but not in total 4-AP bioavailability over the 12-hour study period, was evident between tetraplegic patients, 0."2.69Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ( Brunnemann, SR; Hayes, KC; Hsieh, JT; Mason, D; Pathak, MS; Potter, PJ; Segal, JL; Tierney, DS, 2000)
"Following animal mode studies to establish dosing safety, six subjects with chronic SCI were examined."2.69Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. ( Blight, AR; Calvillo, O; Donovan, WH; Halter, JA, 2000)
" The dose-response characteristics of acutely and chronically injured axons were compared."1.30Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. ( Blight, AR; Kelly, TM; Shi, R, 1997)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.70)18.7374
1990's10 (37.04)18.2507
2000's11 (40.74)29.6817
2010's4 (14.81)24.3611
2020's1 (3.70)2.80

Authors

AuthorsStudies
Villasana-Salazar, B1
Hernández-Soto, R1
Guerrero-Gómez, ME1
Ordaz, B1
Manrique-Maldonado, G1
Salgado-Puga, K1
Peña-Ortega, F1
Giordano, I1
Bogdanow, M1
Jacobi, H1
Jahn, K1
Minnerop, M1
Schoels, L1
Synofzik, M1
Teufel, J1
Klockgether, T1
Simpson, DM1
Goldenberg, J1
Kasner, S1
Nash, M1
Reding, MJ1
Zweifler, RM1
Suarez, G1
Zhao, P1
Henney, HR1
Rabinowicz, AL1
Carrazana, E1
Serafini, R1
Dettloff, S1
Loeb, JA1
Hu, XQ1
Xiao, D1
Zhu, R1
Huang, X1
Yang, S1
Wilson, SM1
Zhang, L1
Grijalva, I1
Guízar-Sahagún, G1
Castañeda-Hernández, G1
Mino, D1
Maldonado-Julián, H1
Vidal-Cantú, G1
Ibarra, A1
Serra, O1
Salgado-Ceballos, H1
Arenas-Hernández, R1
Hayes, KC3
Potter, PJ3
Hsieh, JT3
Katz, MA1
Blight, AR8
Cohen, R2
Wettwer, E1
Hála, O1
Christ, T1
Heubach, JF1
Dobrev, D1
Knaut, M1
Varró, A1
Ravens, U1
Boërio, D1
Lefaucheur, JP1
Hogrel, JY1
Créange, A1
Cardenas, DD1
Ditunno, J1
Graziani, V1
Jackson, AB1
Lammertse, D1
Potter, P1
Sipski, M1
Russell, JW1
Windebank, AJ1
Harper, CM1
Mubagwa, K1
Flameng, W1
Carmeliet, E1
Nagao, T1
Avoli, M1
Gloor, P1
Smirnov, SV1
Robertson, TP1
Ward, JP1
Aaronson, PI1
Hansebout, RR1
Fawcett, S1
Reddy, K1
Bergin, PS1
Miller, DH1
Hirsch, NP1
Murray, NM1
Allatt, RD1
Wolfe, DL1
Lam, S1
Hamilton, JT1
Shi, R1
Kelly, TM1
Haghighi, SS1
Clapper, A1
Johnson, GC1
Stevens, A1
Prapaisilp, A1
Yoshimura, N1
de Groat, WC1
Segal, JL1
Brunnemann, SR1
Pathak, MS1
Tierney, DS1
Mason, D1
Donovan, WH2
Halter, JA2
Graves, DE1
Calvillo, O2
McCann, MT1
Sherwood, AM1
Castillo, T1
Parsons, KC1
Strayer, JR1
van der Bruggen, MA1
Huisman, HB1
Beckerman, H1
Bertelsmann, FW1
Polman, CH1
Lankhorst, GJ1
Workman, AJ1
Kane, KA1
Rankin, AC1
Bonnet, S1
Dubuis, E1
Vandier, C1
Martin, S1
Marthan, R1
Savineau, JP1
Gruner, JA1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial[NCT03899584]Phase 3150 participants (Actual)Interventional2019-07-17Active, not recruiting
Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study[NCT02591901]Phase 248 participants (Actual)Interventional2018-04-06Completed
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma[NCT04026568]Phase 2/Phase 31 participants (Actual)Interventional2021-08-17Terminated (stopped due to Study investigator left Institution)
Pharmaco-Diagnostic Crossover Trial for Peripheral Nerve Continuity After Trauma[NCT06003166]Phase 368 participants (Anticipated)Interventional2024-04-30Not yet recruiting
[NCT00004939]Phase 334 participants Interventional1996-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Subjective Return of Sensation

"Return of lost sensation after nerve injury attributable to circulating 4-AP. Subjective return of sensation in the injured limb or portion of the limb.~Patients for this trial are not able to sense in portions of their limbs. The measure will be sensation, measured on the binary scale of yes or no (able to feel the extremity versus unable to feel) This is assessed through clinical examination of the injured limb." (NCT04026568)
Timeframe: During dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury

Interventionparticipants (Number)
Return of sensation prior to administration of study drug-baselineReturn of sensation 1 hour post study drug administrationReturn of sensation 2 hours post study drug administrationReturn of sensation 3 hours post study drug administrationReturn of sensation 4 hours post study drug administrationReturn of sensation 5 hours post study drug administrationReturn of sensation 2 weeks post injuryReturn of sensation 6 weeks post injuryReturn of sensation 9 weeks post injuryReturn of sensation 12 weeks post injuryReturn of sensation 15 weeks post injuryReturn of sensation 18 weeks post injuryReturn of sensation 20 weeks post injury
Placebo000000000NANANANA

Reviews

1 review available for 4-aminopyridine and Chronic Disease

ArticleYear
[Pathophysiology and treatment of fatigue in multiple sclerosis].
    Revue neurologique, 2006, Volume: 162, Issue:3

    Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N

2006

Trials

10 trials available for 4-aminopyridine and Chronic Disease

ArticleYear
Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.
    Journal of rehabilitation medicine, 2015, Volume: 47, Issue:10

    Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Cross-Over Studies; Do

2015
Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
    Pharmacotherapy, 2003, Volume: 23, Issue:7

    Topics: 4-Aminopyridine; Administration, Oral; Adult; Chronic Disease; Dose-Response Relationship, Drug; Dou

2003
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
    Archives of physical medicine and rehabilitation, 2004, Volume: 85, Issue:1

    Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Female; Huma

2004
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Spinal cord, 2007, Volume: 45, Issue:2

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh

2007
Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
    Mayo Clinic proceedings, 1995, Volume: 70, Issue:6

    Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Aged, 80 and over; Amifampridine; Charcot-Marie-Too

1995
4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
    Journal of neurotrauma, 1993,Spring, Volume: 10, Issue:1

    Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Electrophysiology; F

1993
Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
    Journal of clinical pharmacology, 2000, Volume: 40, Issue:4

    Topics: 4-Aminopyridine; Absorption; Adult; Area Under Curve; Biological Availability; Chronic Disease; Cros

2000
Intravenous infusion of 4-AP in chronic spinal cord injured subjects.
    Spinal cord, 2000, Volume: 38, Issue:1

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Electromyogr

2000
Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.
    Spinal cord, 2000, Volume: 38, Issue:12

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma

2000
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
    Journal of neurology, 2001, Volume: 248, Issue:8

    Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma

2001

Other Studies

16 other studies available for 4-aminopyridine and Chronic Disease

ArticleYear
Chronic intermittent hypoxia transiently increases hippocampal network activity in the gamma frequency band and 4-Aminopyridine-induced hyperexcitability in vitro.
    Epilepsy research, 2020, Volume: 166

    Topics: 4-Aminopyridine; Animals; Chronic Disease; Gamma Rhythm; Hippocampus; Hypoxia, Brain; Male; Nerve Ne

2020
Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
    Journal of neurology, 2013, Volume: 260, Issue:8

    Topics: 4-Aminopyridine; Cerebellar Ataxia; Chronic Disease; Disability Evaluation; Humans; Potassium Channe

2013
Neocortical slices from adult chronic epileptic rats exhibit discharges of higher voltages and broader spread.
    Neuroscience, 2016, May-13, Volume: 322

    Topics: 4-Aminopyridine; Animals; Chronic Disease; Disease Models, Animal; Electrocorticography; Epilepsy; I

2016
Chronic hypoxia suppresses pregnancy-induced upregulation of large-conductance Ca2+-activated K+ channel activity in uterine arteries.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:1

    Topics: 4-Aminopyridine; Acclimatization; Altitude; Animals; Blotting, Western; Cells, Cultured; Chronic Dis

2012
Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: 4-Aminopyridine; Action Potentials; Aged; Atrial Appendage; Atrial Fibrillation; Biphenyl Compounds;

2004
Resting and action potentials of nonischemic and chronically ischemic human ventricular muscle.
    Journal of cardiovascular electrophysiology, 1994, Volume: 5, Issue:8

    Topics: 4-Aminopyridine; Action Potentials; Chronic Disease; Diacetyl; Epinephrine; Heart; Humans; In Vitro

1994
Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures.
    Neuroscience letters, 1994, Jun-20, Volume: 174, Issue:2

    Topics: 4-Aminopyridine; Animals; Chronic Disease; Electrophysiology; Evoked Potentials; Hippocampus; In Vit

1994
Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells.
    The American journal of physiology, 1994, Volume: 266, Issue:1 Pt 2

    Topics: 4-Aminopyridine; Animals; Chronic Disease; Electric Conductivity; Electrophysiology; Glyburide; Hypo

1994
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
    Annals of neurology, 1993, Volume: 34, Issue:3

    Topics: 4-Aminopyridine; Amifampridine; Chronic Disease; Demyelinating Diseases; Humans; Neural Conduction;

1993
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury.
    Paraplegia, 1993, Volume: 31, Issue:4

    Topics: 4-Aminopyridine; Adult; Blood Pressure; Body Temperature; Chronic Disease; Drug Evaluation; Electroe

1993
Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine.
    Experimental neurology, 1997, Volume: 148, Issue:2

    Topics: 4-Aminopyridine; Action Potentials; Acute Disease; Animals; Chronic Disease; Dose-Response Relations

1997
Effect of 4-aminopyridine and single-dose methylprednisolone on functional recovery after a chronic spinal cord injury.
    Spinal cord, 1998, Volume: 36, Issue:1

    Topics: 4-Aminopyridine; Animals; Behavior, Animal; Chronic Disease; Glucocorticoids; Male; Methylprednisolo

1998
Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1999, Jun-01, Volume: 19, Issue:11

    Topics: 4-Aminopyridine; Action Potentials; Animals; Chronic Disease; Cyclophosphamide; Cystitis; Female; Ga

1999
The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation.
    Cardiovascular research, 2001, Volume: 52, Issue:2

    Topics: 4-Aminopyridine; Action Potentials; Aged; Atrial Fibrillation; Atrial Function; Calcium Channel Bloc

2001
Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing.
    Cardiovascular research, 2002, Volume: 53, Issue:4

    Topics: 4-Aminopyridine; Animals; Blood Pressure; Calcium; Cells, Cultured; Chronic Disease; Electrophysiolo

2002
Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats.
    Journal of the neurological sciences, 1987, Volume: 82, Issue:1-3

    Topics: 4-Aminopyridine; Aminopyridines; Animals; Cats; Chronic Disease; Efferent Pathways; Electromyography

1987